To enhance the therapeutic efficacy of MSCs for immune-mediated diseases, we engineered MSCs to overexpress human IL-10 (hIL-10) and evaluated their therapeutic efficacy in an acute GvHD (aGvHD) model. Here, IL10 is linked to graft versus host disease.